Adenosquamous carcinoma of the lung

Li, Chenghui; Lu, Hongyang

doi:10.2147/ott.s164574

Cited by 80 publications

(71 citation statements)

References 57 publications

(81 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Besides, lung ASC had higher grade malignancy, stronger lymph nodal invasiveness, more frequent brain metastases and poorer prognosis than lung adenocarcinoma (ADC) and SCC [12]. However, in other studies, there were also ASC in some site behaved similar with common type.…”

Section: Discussionmentioning

confidence: 82%

Adenosquamous Carcinoma of the Breast: A Population-Based Study Using the SEER Database

Liu

Lin

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: The present study is aimed at summarizing the clinicopathological characteristics, prognosis, and management of breast adenosquamous carcinoma (ASC). Methods: A population-based study was performed using retrospectively extracted data from the Surveillance, Epidemiology and End Results database for breast cancer patients with histological diagnoses of ASC, infiltrating duct carcinoma (IDC) and squamous cell carcinoma (SCC) from 2004 to 2016. End-points were overall survival (OS) and breast cancer-specific mortality (BCSM). Propensity Score Matching (PSM) was employed to minimize selection bias of baseline characteristics. Univariable and multivariable analyses were used for identifying valuable prognostic factors. Results: ASC presented similar tumor size but low histological grade and less lymph node metastasis compared to IDC. ASC expressed less positive rate of hormone receptors and barely HER2, which was similar with SCC (estrogen receptor (ER): ASC 27.74% and SCC 21.53%, progesterone receptor (PR): ASC 18.06% and SCC 12.85%, HER2: ASC 4.44% and SCC 7.53%). ASC patients underwent the same treatment as IDC (chemotherapy 36.99% vs. 41.86%, BCS 50.58% vs 52.83%, P >0.05), only with less radiotherapy (39.88% vs. 48.34%, P<0.05). Median follow-up data of 78 months showed that the prognosis of IDC patients was better than that of ASC patients (all P <0.05 for BCSM and OS). After adjustment for clinicopathological and therapeutic factors in Cox proportional hazards models, ASC was no longer an independent poor prognosis factor. In matched groups, no significant difference in BCSM nor OS was observed between ASC and IDC groups. In HR-negative patients, the prognosis of ASC was similar with that of IDC, and both were superior to SCC. In HR-positive patients, the five-year survival rate of ASC was only about 60%, which was far less than that in ASC of HR-negative, the poor prognosis of ASC was closer to that of SCC. Multivariate analysis showed that older age (age≥60) and advanced AJCC stage (III and IV) were independent factors of poor prognosis in ASC, breast-conserving surgery was also ideally suited for ASC. Conclusions: ASC has unique clinicopathological characteristics and prognosis. To improve the clinical and biological understanding of ASC can make breast cancer patients get more individualized treatment.

show abstract

Section: Discussionmentioning

confidence: 82%

Adenosquamous Carcinoma of the Breast: A Population-Based Study Using the SEER Database

Liu

Lin

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…In 1978, the Japanese Lung Cancer Society reported that to be able to diagnose ASC, components of SCC and adenocarcinoma have to constitute 20% of each tumor [15]. In the last WHO classification, it is required for each component to form 10% of the tumor [16]. Pleomorphic, fusiform cell and giant cell carcinomas constitute less than 3% of lung cancers [11].…”

Section: Discussionmentioning

confidence: 99%

Trends in lung cancer incidence within the last 10 years: An Eastern Anatolian single center experience

Özmen¹

2020

Journal of Surgery and Medicine

View full text Add to dashboard Cite

Aim: Lung cancer is the most common cause of cancer-related deaths among men and women, and mortality and morbidity rates vary according to different histological groups. Therefore, histological type determination is extremely important. The purpose of the study is to investigate the histological subtypes of lung cancer cases within the last 10 years in one of the biggest centers of the Eastern Anatolian Region, considering the changes made in the 2015 updates in lung tumors by World Health Organization (WHO), and investigate the relationship between these histological sub-types and distribution according to year, gender and age. Methods: In this cross-sectional study, patients who were referred for lung biopsy between January 2010 and December 2019 and diagnosed with lung carcinoma were retrospectively analyzed. Results: Our study shows that the frequency of lung cancer, along with histological subtypes, has increased throughout the years. The most common lung cancer type, regardless of gender, is Squamous Cell Carcinoma (SCC), followed by Small Cell Lung Carcinoma (SCLC) and Adenocarcinoma. Adenocarcinoma and SHC were the most common subtypes among females and males, respectively. A significant relationship was observed between gender and histological type (P<0.001). Conclusion: The data from our study suggest that the incidence of lung cancer increased throughout the years, similar to the data from our country and other developing countries around the world. In terms of subtypes, among developing countries, Adenocarcinoma rate increased while SCC rate decreased. In our study, the most common histological types increased at a similar rate. Adenocarcinoma was the most common lung cancer among females, similar to other developing countries. The most common lung cancer overall remained the same: SCC. This was considered an indication of the unchanged smoking habits of males.

show abstract

“…However, since some COSMIC cases precede this classification, we will still use the term bronchioalveolar in this report. Squamous cell carcinoma and adenosquamous carcinoma are the two other forms of lung cancer [25] reported on COSMIC. "Non-small cell carcinoma" refers to non-classified NSCLC or unknown origin.…”

Section: Classificationmentioning

confidence: 99%

Secondary Resistant Mutations to Small Molecule Inhibitors in Cancer Cells

Hamid

Petreaca

2020

Cancers

View full text Add to dashboard Cite

Secondary resistant mutations in cancer cells arise in response to certain small molecule inhibitors. These mutations inevitably cause recurrence and often progression to a more aggressive form. Resistant mutations may manifest in various forms. For example, some mutations decrease or abrogate the affinity of the drug for the protein. Others restore the function of the enzyme even in the presence of the inhibitor. In some cases, resistance is acquired through activation of a parallel pathway which bypasses the function of the drug targeted pathway. The Catalogue of Somatic Mutations in Cancer (COSMIC) produced a compendium of resistant mutations to small molecule inhibitors reported in the literature. Here, we build on these data and provide a comprehensive review of resistant mutations in cancers. We also discuss mechanistic parallels of resistance.

show abstract

Adenosquamous carcinoma of the lung

Cited by 80 publications

References 57 publications

Adenosquamous Carcinoma of the Breast: A Population-Based Study Using the SEER Database

Adenosquamous Carcinoma of the Breast: A Population-Based Study Using the SEER Database

Trends in lung cancer incidence within the last 10 years: An Eastern Anatolian single center experience

Secondary Resistant Mutations to Small Molecule Inhibitors in Cancer Cells

Contact Info

Product

Resources

About